Abstract Library

#4614 Rare diagnosis of intrapancreatic accessory spleen mimicking PanNET

Introduction: A 44-year-old woman with hypertension and an autoimmune thyroid disease. With a positive family history of pancreatic and oesophageal cancer. Referred to our clinic for an incidental finding of a tumour in the tail of the pancreas on abdominal ultrasound by a surgeon.

Conference:

Presenting Author: Uhrík P

Authors: Uhrík P, Nosakova L, Vojtko M, Bánovčin P,

Keywords: fine needle biopsy, accessory spleen, Neuroendocrine tumour,

#4591 Efficacy of Trabectedin and Olaparib in homologous repair deficient neuroendocrine neoplasms – A subgroup analysis of the TOP-ART / PMO-1603 trial

Introduction: Genomic alterations resulting in homologous recombination deficiency (HRD) occur in a variety of cancers including neuroendocrine neoplasms (NEN). HRD-positive tumours are sensitive to PARP inhibitors such as olaparib. The DNA minor groove binder trabectedin leads to DNA double strand breaks and PARP activation. The combination of Trabectedin + Olaparib (TrO) may therefore have synergistic effects in HRD-positive tumours.

Conference:

Presenting Author: Apostolidis L

Authors: Apostolidis L, Ruebsam M, Teleanu M, Wagner S, Dorman K,

Keywords: Neuroendocrine Tumour, Neuroendocrine Carcinoma, targeted therapy, chemotherapy, HRD, olaparib, trabectedin, net, nec,

#4523 Preoperative evaluation of tumour border using radiomics and its surgical guidance in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine tumours are a heterogeneous group of tumours originating from peptidergic neurons and neuroendocrine cells with variable survival outcomes. Surgical resection is the mainstay of treatment. However, there is an ambiguous insight into the real need to execute the standard surgery in small pancreatic neuroendocrine tumours. The tumour border is a powerful determinant of survival prognosis in many tumours and is often used as a safety guarantee for parenchyma-sparing resections. However, there are no studies evaluating tumour border with or without preoperative imaging in pNETs.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Gu W, Tang W, Huang D, Zhang W,

Keywords: pancreatic neuroendocrine tumour, border, computed tomography, enucleation, radiomics,

#4502 Molecular analysis of non-functioning PanNETs of the alpha lineage reveals new subtypes and mechanisms of progression

Introduction: Most pancreatic neuroendocrine tumours (PanNETs) are non-functioning. Previously, we demonstrated that small, MEN1-only mutated α-like PanNETs can be distinguished from larger ADM (mutated in ATRX, DAXX and MEN1) PanNETs based on epigenetic profiles. ADM PanNETs have shorter disease-free survival and a higher relapse risk. However, their therapeutic responses vary, underscoring group heterogeneity. ADM PanNETs remain insufficiently characterised, with potential subtype-specific progression drivers with implications for treatment choice and clinical outcome.

Conference:

Presenting Author: Avanthay S

Authors: Avanthay S, Di Domenico A, Kirchner P, Bräutigam K, Chouchane A,

Keywords: pancreas, epigenetics, progression, metastasis, DAXX, ATRX, Pan NET,

#4451 The management of well-differentiated gastroenteropancreatic neuroendocrine tumours in a tertiary centre – The contribution of radionuclide therapy

Introduction: Neuroendocrine tumours represent a heterogenous group of tumours with different locations, whose management is necessary to identify specific parameters that determine the choice of optimal treatment.

Conference:

Presenting Author: Oana Stefania S

Authors: Oana Stefania S, Corin B, Victoria V, Sofia L,

Keywords: GEP-NET, well-differentiated, PRRT, Cromogranine A, Serotonin, RECIST 1.1,